Compare CCSI & EDIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CCSI | EDIT |
|---|---|---|
| Founded | 2021 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 493.6M | 432.8M |
| IPO Year | 2022 | 2016 |
| Metric | CCSI | EDIT |
|---|---|---|
| Price | $34.85 | $2.38 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | ★ $37.50 | $5.30 |
| AVG Volume (30 Days) | 152.9K | ★ 3.3M |
| Earning Date | 05-07-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 37.50 |
| EPS | ★ 1.30 | N/A |
| Revenue | ★ $349,696,000.00 | $31,937,000.00 |
| Revenue This Year | $3.33 | N/A |
| Revenue Next Year | $2.70 | N/A |
| P/E Ratio | $26.66 | ★ N/A |
| Revenue Growth | N/A | ★ 132.64 |
| 52 Week Low | $19.42 | $1.66 |
| 52 Week High | $37.30 | $4.54 |
| Indicator | CCSI | EDIT |
|---|---|---|
| Relative Strength Index (RSI) | 64.62 | 38.14 |
| Support Level | $25.76 | $2.24 |
| Resistance Level | $36.73 | $2.76 |
| Average True Range (ATR) | 1.84 | 0.25 |
| MACD | 0.01 | -0.06 |
| Stochastic Oscillator | 78.60 | 2.44 |
Consensus Cloud Solutions Inc is a provider of secure information delivery services with a scalable Software-as-a-Service SaaS platform. It is engaged in the fax cloud business. The company's offerings include communication, data extraction, and digital signature solutions that enable users to securely access, exchange, and manage information across organizational and geographic boundaries. It serves multiple industry verticals, including healthcare, government, financial services, legal, and education. Geographically, the company operates in the United States, Canada, Ireland, and other countries. It derives the maximum revenue from the United States.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary gene editing platform based on CRISPR technology and continues to expand its capabilities. CRISPR uses a protein-RNA complex composed of an enzyme, including either Cas9 (CRISPR-associated protein 9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1). The company has a single operating segment, which is the business of developing and commercializing gene editing technology.